Renowned Ophthalmologist joins to the team to accelerate development of early detection solutions with AI for retinal imaging
Houston, Texas, 27th January 2023, ZEXPRWIRE, The leading AI-based software company, Ainnova Tech, is proud to announce the addition of Dr. Maziar Lalezary to its team of medical advisors. Dr. Lalezary joins the medical team along with Dr. Lihteh Wu, Chief Medical Officer and a world-renowned retinologist who has made significant contributions to the field of medical research, as well as being an inductee into the Retina Hall of Fame.
Dr. Lalezary is a highly accomplished neuroscientist and ophthalmologist, with a wealth of experience in both academic and clinical settings. He earned his undergraduate degree in neuroscience from UCLA, where he graduated summa cum laude. He then went on to complete his medical degree at the University of California, San Diego School of Medicine. After completing his ophthalmology residency at the Vanderbilt Eye Institute, he completed a vitreo-retinal fellowship as a distinguished Gass Fellow.
According to Ainnova Tech’s CEO, Vinicio Vargas, the addition of Dr. Lalezary is part of the company’s strategy to increase its team of retina specialists for the validation and labeling of diseases in retina images, as well as to have his contributions and advice in the FDA process that is about to begin.
“Dr. Lalezary is a highly recognized ophthalmologist in the US and an innovator. We are very excited to welcome him to our medical board and are confident that his contributions will be invaluable,” said Vinicio Vargas, CEO of Ainnova Tech.
Dr. Lalezary is dedicated to advancing the field through research and delivering state-of-the-art care to patients. As a Health tech company that uses AI to develop solutions for the early detection of diseases with an eye fundus image, Dr. Lalezary’s expertise in ophthalmology will be invaluable as the company continues to innovate and improve its offerings.
“I’m honored to join the team and excited to work on an innovative platform that will harness the power of AI to improve the lives of patients.” said Dr. Lalezary.
The company is committed to providing cutting-edge solutions for the early detection of diseases through AI-based technology. With the addition of Dr. Lalezary to its team of medical advisors, the company is well-positioned to continue to innovate and improve its offerings for the benefit of patients worldwide.
Ainnova Tech is a Nevada Company headquartered in Houston, Texas and San Jose, Costa Rica. The health tech startup has as its purpose to “Create the future of early detection of diseases in an accessible way.
Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as “will,” “may,” “should,” “could,” “intend,” “estimate,” “plan,” “anticipate,” “expect,” “believe,” “potential” or “continue,” or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Diana Quesada, Director, Marketing & Communications
Company Name:-Ainnova Tech
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No A News Week journalist was involved in the writing and production of this article.